Commissioner highlights obstacles to innovation
This article was originally published in Clinica
Executive Summary
Enterprises working with novel biotechnologies do not know if they are fully allowed to reap the commercial benefits of their work." That was one of the key concerns expressed by European Commissioner in charge of research, Philippe Busquin, when he addressed the general assembly of the European biotechnology trade association, EuropaBio, on June 24.